Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Conavi Medical ( (TSE:CNVI) ).
Conavi Medical highlights a new study in The American Journal of Cardiology that emphasizes the importance of intracoronary imaging (ICI) during percutaneous coronary interventions (PCI). The study reveals that while ICI significantly improves PCI outcomes, it remains underutilized, with only 13.5% of patients receiving image-guided PCI by 2020. Conavi’s Novasight Hybrid System, which combines IVUS and OCT imaging, is positioned to address barriers to ICI adoption, such as technical training and procedural complexity, and is expected to benefit from recent guideline upgrades promoting ICI use. This development underscores Conavi’s strategic positioning in the market and its potential impact on improving coronary care.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a company specializing in the design, manufacturing, and marketing of imaging technologies for minimally invasive cardiovascular procedures. Their flagship product, the Novasight Hybrid System, is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries. The system has received regulatory approval from multiple international health authorities.
Average Trading Volume: 68,601
Technical Sentiment Signal: Sell
Current Market Cap: C$27.26M
For detailed information about CNVI stock, go to TipRanks’ Stock Analysis page.